- 関
- cyclophosphamide
UpToDate Contents
全文を閲覧するには購読必要です。 To read the full text you will need to subscribe.
English Journal
- A new disposable electrode for electrochemical study of leukemia K562 cells and anticancer drug sensitivity test.
- Yu C, Zhu Z, Wang L, Wang Q, Bao N, Gu H.Author information Institute of Analytical Chemistry for Life Science, School of Public Health, Nantong University, Nantong 226019, PR China.AbstractDeveloping cost-effective and simple analysis tools is of vital importance for practical applications in bioanalysis. In this work, a new disposable electrochemical cell sensor with low cost and simple fabrication was proposed to study the electrochemical behavior of leukemia K562 cells and the effect of anticancer drugs on cell viability. The analytical device was integrated by using ITO glass as the substrate of working electrodes and paper as the electrolytic cell. The cyclic voltammetry of the K562 cells at the disposable electrode exhibited an irreversible anodic peak and the peak current is proportional to the cell number. This anodic peak is attributed to the oxidation of guanine in cells involving two protons per transfer of two electrons. For the drug sensitivity tests, arsenic trioxide and cyclophosphamide were added to cell culture media. As a result, the electrochemical responses of the K562 cells decreased significantly. The cytotoxicity curves and results obtained corresponded well with the results of CCK-8 assays. In comparison to conventional methods, the proposed method is simple, rapid and inexpensive. More importantly, the developed sensor is supposed to be a single-use disposable device and electrodes were prepared "as new" for each experiment. We think that such disposable electrodes with these characteristics are suitable for experimental study with cancer cells or other types of pathogens for disease diagnosis, drug selection and on-site monitoring.
- Biosensors & bioelectronics.Biosens Bioelectron.2014 Mar 15;53:142-7. doi: 10.1016/j.bios.2013.09.044. Epub 2013 Oct 2.
- Developing cost-effective and simple analysis tools is of vital importance for practical applications in bioanalysis. In this work, a new disposable electrochemical cell sensor with low cost and simple fabrication was proposed to study the electrochemical behavior of leukemia K562 cells and the effe
- PMID 24140828
- Outcome of patients with HER2-positive breast cancer treated with or without adjuvant trastuzumab in the Finland Capecitabine Trial (FinXX).
- Joensuu H, Kellokumpu-Lehtinen PL, Huovinen R, Jukkola-Vuorinen A, Tanner M, Kokko R, Ahlgren J, Auvinen P, Saarni O, Helle L, Villman K, Nyandoto P, Nilsson G, Leinonen M, Kataja V, Bono P, Lindman H.Author information Department of Oncology, Helsinki University Central Hospital , Helsinki , Finland.AbstractAbstract Background. Little information is available about survival outcomes of patients with HER2-positive early breast cancer treated with adjuvant capecitabine-containing chemotherapy with or without trastuzumab. Patients and methods. One thousand and five hundred patients with early breast cancer were entered to the Finland Capecitabine trial (FinXX) between January 2004 and May 2007, and were randomly assigned to receive either three cycles of adjuvant TX (docetaxel, capecitabine) followed by three cycles of CEX (cyclophosphamide, epirubicin, capecitabine; TX-CEX) or three cycles of docetaxel followed by three cycles of CEF (cyclophosphamide, epirubicin, fluorouracil; T-CEF). The primary endpoint was recurrence-free survival (RFS). The study protocol was amended in May 2005 while study accrual was ongoing to allow adjuvant trastuzumab for patients with HER2-positive cancer. Of the 284 patients with HER2-positive cancer accrued to FinXX, 176 (62.0%) received trastuzumab after amending the study protocol, 131 for 12 months and 45 for nine weeks. The median follow-up time was 6.7 years. Results. Patients with HER2-positive cancer who received trastuzumab had better RFS than those who did not (five-year RFS 89.2% vs. 75.9%; HR 0.41, 95% CI 0.23-0.72; p = 0.001). Patients treated with trastuzumab for 12 months or nine weeks had similar RFS. There was no significant interaction between trastuzumab administration and the type of chemotherapy. Four (2.3%) patients treated with trastuzumab had heart failure or left ventricular dysfunction, three of these received capecitabine. Conclusion. Adjuvant trastuzumab improves RFS of patients treated with TX-CEX or T-CEF. Few patients had cardiac failure.
- Acta oncologica (Stockholm, Sweden).Acta Oncol.2014 Feb;53(2):186-94. doi: 10.3109/0284186X.2013.820840. Epub 2013 Aug 19.
- Abstract Background. Little information is available about survival outcomes of patients with HER2-positive early breast cancer treated with adjuvant capecitabine-containing chemotherapy with or without trastuzumab. Patients and methods. One thousand and five hundred patients with early breast cance
- PMID 23957715
- A case of pemphigoid gestationis with concurrent IgG antibodies to BP180, BP230 and type VII collagen.
- Yang B, Wang C, Wu M, Du D, Yan X, Zhou G, Zhang F.Author information Shandong Provincial Institute of Dermatology and Venereology, Shandong Provincial Academy of Medical Science; Shandong Provincial Key Lab for Dermatovenereology.AbstractA 22-year-old primigravida had a pruritic, erythematous, bullous eruption on the skin during the 26th week of gestation. After delivery the eruption flared up. The diagnosis of pemphigoid gestationis was confirmed based on histopathological and immunofluorescence findings. The result of immunoblotting showed IgG autoantibodies which reacted against BP230 in epidermal extracts and 290 kDa type VII collagen in dermal extracts. The BP180 antibodies were also detected by an enzyme-linked immunosorbent assay BP180NC16a diagnosis kit. Pulsed corticosteroid and cyclophosphamide resulted in a favourable response at the acute stage. The patient was cured in 2 years. The analysis of the patient's autoantibodies provides strong evidence for the involvement of epitope spreading in her autoimmune disease.
- The Australasian journal of dermatology.Australas J Dermatol.2014 Feb;55(1):e15-8. doi: 10.1111/j.1440-0960.2012.00960.x. Epub 2012 Oct 22.
- A 22-year-old primigravida had a pruritic, erythematous, bullous eruption on the skin during the 26th week of gestation. After delivery the eruption flared up. The diagnosis of pemphigoid gestationis was confirmed based on histopathological and immunofluorescence findings. The result of immunoblotti
- PMID 23082779
Japanese Journal
- 116 悪性奇形腫群腫瘍進行例に対するCisplatin, Cytoxan, Adriamycin(CCA)併用療法
- 見須 英雄,馬渕 理,西島 栄治,連 利博,津川 力,松本 陽一,杉村 千恵,橋本 公夫,伊東 宏
- 日本小児外科学会雑誌 23(2), 369, 1987-04-20
- NAID 110002082018
- A comparison of Cytoxan, Adriamycin and 5-FU(CAF) and Cytoxan, methotrexate,5-FU, vincristine and prednisone (CMFVP) in patients with advanced breast cancer : A Southern Cnacer Study Group Project
- 134. The effects of chloroquine on the teratogenicity of cytoxan in mice
- JIRAKULSOMCHOK S,YIELDING.L K,YIELDING.W L,DAGG.P C
- 先天異常 : 日本先天異常学会会報 : official journal of Congeital Anomalies Research Association of Japan 19(3), 226, 1979-09-30
- NAID 110002727091
Related Links
- Learn about the prescription medication Cytoxan (Cyclophosphamide), drug uses, dosage, side effects, drug interactions, warnings, reviews and patient labeling. ... What are the possible side effects of cyclophosphamide (Cytoxan ...
- シクロホスファミド(Cytoxan)抗腫瘍薬シクロホスファミド(Cytoxan)です。 抗腫瘍薬の個人輸入のサイトです。--- --- 本物 ... e-world in your hands (STAR-LIN Herb Corp.,USA) 海外の個人輸入・情報サイトです。 検索結果を表示 海外の動物の ...
★リンクテーブル★
[★]
- 同
- Cytoxan, Neosar
- 関
- Cyclophosphamide
- 関
- cyclophosphamide